Linezolid Krka (Linezolid)

Linezolid is indicated for several serious bacterial infections caused by Gram‑positive organisms.

• Complicated skin and soft tissue infections: effective against susceptible pathogens, reducing infection severity.
• Community‑acquired and nosocomial pneumonia: provides bacterial clearance in lung infections caused by susceptible organisms.
• Infections caused by methicillin‑resistant Staphylococcus aureus (MRSA): achieves bacteriostatic activity against MRSA strains.
• Infections caused by vancomycin‑resistant Enterococcus (VRE): offers an alternative treatment option for VRE infections.
• Other infections caused by susceptible Gram‑positive bacteria: resolves infections where other agents may be ineffective.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex required for translation. This blocks the elongation step of protein production, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms, including MRSA and VRE, and retains activity against strains resistant to beta‑lactams and glycopeptides.

Linezolid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Thrombocytopenia: reduced platelet count, usually reversible.
• Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects

• Myelosuppression: severe bone‑marrow suppression leading to anemia or neutropenia.
• Peripheral neuropathy: nerve damage causing sensory disturbances.
• Lactic acidosis: rare metabolic acidosis requiring immediate medical attention.
• Serotonin syndrome: risk when combined with serotonergic agents.

When prescribing Linezolid, clinicians should consider several safety measures.

• Renal impairment: monitor kidney function and adjust therapy as needed.
• Hepatic dysfunction: assess liver enzymes before and during treatment.
• Hematologic monitoring: perform regular blood counts to detect thrombocytopenia or anemia.
• Concomitant serotonergic drugs: avoid or use with caution due to serotonin syndrome risk.
• Pregnancy and lactation: use only if benefits outweigh potential risks; limited data available.
• Store at ambient temperature: keep vials in original packaging, protect from light and moisture, and do not freeze.

Linezolid interacts with several drug classes; careful assessment is required.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs): may precipitate serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin toxicity.
• Tricyclic antidepressants: potential additive serotonergic effects.
• Rifampicin: reduces linezolid plasma concentrations, compromising efficacy.
• Tyramine‑rich foods: may exacerbate hypertensive reactions when combined with MAOIs.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect; monitor INR.
• Ethanol: possible disulfiram‑like reaction; advise caution.
• NSAIDs: increase bleeding risk if thrombocytopenia occurs.
• Digoxin: monitor levels as linezolid may affect clearance.
• Anticonvulsants (e.g., carbamazepine): may alter linezolid metabolism.